摘要
目的近年来蒽环类化疗失败复发转移性乳腺癌现象时常发生,将对患者造成更加严重的不良影响,需要采取良好的措施进行治疗。本研究探讨多西他赛联合卡培他滨治疗蒽环类化疗失败复发转移性乳腺癌的临床疗效。方法选取2018-02-01-2019-02-01许昌市人民医院收治的80例蒽环类化疗失败复发转移性乳腺癌患者为研究对象,依据临床采取的治疗方式选择对照组与观察组,各40例。对照组采用多西他赛联合顺铂治疗,观察组采用多西他赛联合卡培他滨治疗。观察两组患者的总缓解率及不良反应。结果观察组总缓解率为92.50%,高于对照组的72.50%,差异有统计学意义,χ2=5.541,P=0.019;观察组不良反应发生率为15.00%,低于对照组的42.50%,差异有统计学意义,χ2=7.384,P=0.007。结论多西他赛联合卡培他滨治疗蒽环类化疗失败复发转移性乳腺癌具有较好的临床效果,且不良反应发生率较低。
OBJECTIVE This paper aims to investigate the clinical efficacy of Tessordi combined with Heroda in the treatment of recurrent metastatic breast cancer with failed anthracycline chemotherapy.METHODS From February 1,2018 to February 1,2019,the patients with anthracyclines chemotherapy failure,recurrence and metastatic breast cancer in our hospital were studied.The control group(n=40)and the observation group(n=40)were selected according to the clinical treatment methods,and the control group was treated with docetaxel combined with cis-platinum and the observation group was treated with docetaxet and capecitabine.The total remission rate and adverse reactions of the two groups were observed.RESULTS The total remission rate of lesions in the observation group was 92.50%,which was significantly higher than that in the control group(72.50,χ2=5.541,P=0.019),and the incidence of adverse reactions was15.00%,which was significantly lower than that in the control group(42.50%,χ2=7.384,P=0.007).CONCLUSION The treatment of anthracyclines with docetaxel and capecitabine has remarkable clinical effect on recurrent metastatic breast cancer with low incidence of adverse reactions.
作者
金俊超
徐晓战
JIN Jun-chao;XU Xiao-zhan(Department of Breast Surgery,Xuchang People’s Hospital,Xuchang 461000,P.R.China)
出处
《社区医学杂志》
2020年第12期869-871,共3页
Journal Of Community Medicine
关键词
多西他赛
卡培他滨
蒽环类化疗失败
复发转移性乳腺癌
docetaxel
capecitabine
failure of anthracycline chemotherapy
recurrent and metastatic breast cancer
